Pharmacomechanical Thrombolysis for Acute DVT Tied to Kidney Injury
THURSDAY, Aug. 5, 2021 -- Use of pharmacomechanical thrombolysis (PMT) for treatment of acute deep vein thrombosis (DVT) is associated with a risk for acute kidney injury (AKI) that can progress to chronic renal failure in some patients, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 5, 2021 Category: Pharmaceuticals Source Type: news
Behcet's Syndrome Presenting With Pulmonary Artery Thrombosis Behcet's Syndrome Presenting With Pulmonary Artery Thrombosis
This case demonstrates how early detection of vascular involvement can have a major impact on the prognosis of patients with Behcet ' s syndrome.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 5, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
NICE guideline - blood clotting condition associated with COVID-19 vaccination
NICE has published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations. (Source: NHS Networks)
Source: NHS Networks - August 2, 2021 Category: UK Health Source Type: news
COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) [NG200], NICE (published 29th July 2021)
This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VITT is a new condition, there is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome. (Source: Current Awaren...
Source: Current Awareness Service for Health (CASH) - July 29, 2021 Category: Consumer Health News Source Type: news
Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS) following vaccination with an mRNA vaccine or Vaxzevria, and compared them with expected rates in a general population and in people with COVID-19. (Source: World Pharma News)
Source: World Pharma News - July 28, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Rare blood clot cases not higher after AstraZeneca second dose: Study
The data found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the vaccine, Vaxzevria, was 2.3 per million in those inoculated, comparable to the typical rate seen in those who have not been vaccinated, AstraZeneca said. (Source: The Economic Times)
Source: The Economic Times - July 28, 2021 Category: Consumer Health News Source Type: news
VTE Risk Up for Children With Inflammatory Bowel Disease
Venous thromboembolism occurred less often for those with Crohn disease versus ulcerative colitis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 27, 2021 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Internal Medicine, Oncology, Pediatrics, Pharmacy, Journal, Source Type: news
VTE Risk Up for Children With Inflammatory Bowel Disease
TUESDAY, July 27, 2021 -- Children with inflammatory bowel disease (IBD) have a higher risk for venous thromboembolism (VTE), according to a study published online June 27 in the Journal of Crohn ' s& Colitis.
M. Ellen Kuenzig, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 27, 2021 Category: Pharmaceuticals Source Type: news
Abelacimab Prevents VTE After Total Knee Arthroplasty
Single, postoperative IV dose of abelacimab superior to enoxaparin for preventing venous thromboembolism, with no increase in bleeding risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 26, 2021 Category: Cancer & Oncology Tags: Oncology, Orthopedics, Pharmacy, Surgery, Conference News, Source Type: news
Abelacimab Prevents VTE After Total Knee Arthroplasty
MONDAY, July 26, 2021 -- For patients undergoing total knee arthroplasty, abelacimab, a monoclonal antibody that binds to factor XI and locks it in the zymogen conformation, is effective for preventing venous thromboembolism without increasing the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 26, 2021 Category: Pharmaceuticals Source Type: news
Organs From Deceased Recipients of AstraZeneca COVID-19 Vaccine May Pose Problems Organs From Deceased Recipients of AstraZeneca COVID-19 Vaccine May Pose Problems
Organs from deceased donors who had received AstraZeneca ' s vaccine against SARS-CoV-2 may possibly prompt vaccine-induced thrombosis and thrombocytopenia in recipients, according to a new study.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - July 24, 2021 Category: Transplant Surgery Tags: Infectious Diseases News Source Type: news
Risk Factors ID'd for VTE, ASCVD in Rheumatoid Arthritis Patients
FRIDAY, July 23, 2021 -- For patients with rheumatoid arthritis (RA), there are common risk factors for venous thromboembolism (VTE) and atherosclerotic cardiovascular disease (ASCVD), and the risk for ASCVD is increased after unprovoked VTE,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 23, 2021 Category: Pharmaceuticals Source Type: news
Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
Benny Sorensen appointed Chief Executive Officer and Co-Founder Johan Henrik Faber appointed Chief Technology Officer
Financing led by Novo Holdings, HealthCap and RA Capital Management
Advancing pipeline of bispecific and monoclonal antibodies with ... Biopharmaceuticals, Venture Capital Hemab , thrombosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 22, 2021 Category: Pharmaceuticals Source Type: news
Five Risk Factors May Predict Thrombus on LAA Occlusion Implants Five Risk Factors May Predict Thrombus on LAA Occlusion Implants
Some are known, some are new, and when pulled together to create a new clinical risk score, patients deemed at high risk showed a twofold increased rate of this worrisome complication.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 21, 2021 Category: Surgery Tags: Cardiology News Source Type: news
Abelacimab Prevents VTE and Bleeding Risk in Knee Replacement Abelacimab Prevents VTE and Bleeding Risk in Knee Replacement
A monoclonal antibody that inhibits factor XI effectively reduces thromboembolism risk for knee-replacement patients, a new study suggests.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - July 19, 2021 Category: Orthopaedics Tags: Orthopaedics News Source Type: news
